Stockreport

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation

IGC Pharma, Inc.  (IGC) 
NASDAQ:AMEX Investor Relations: igcinc.us/investor-center/overview
PDF - Interim Data: Study Achieves Primary End Point Demonstrating Clinical and Statistically Significant Reductions Compared to Placebo in Agitation Associated with Dementi [Read more]